Cargando…

Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease

Ethnopharmacological Relevance. The Hugan Qingzhi tablet (HQT) is a traditional Chinese medicine used for treating NAFLD (nonalcoholic fatty liver disease). The present study evaluated the anti-inflammatory effects of HQT in rats with NAFLD. Materials and Methods. HQT was administered daily to the N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, WaiJiao, Zeng, Lu, Yin, JinJin, Yao, YuFa, Feng, LiJuan, Yao, XiaoRui, Sun, XiaoMin, Zhou, BenJie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471380/ https://www.ncbi.nlm.nih.gov/pubmed/26146507 http://dx.doi.org/10.1155/2015/810369

Ejemplares similares

Data for iTRAQ-based quantification of the effect of HuganQingzhi on non-alcoholic fatty liver disease in rats
por: Yao, Xiaorui, et al.
Publicado: (2017)

Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease
por: Tang, Waijiao, et al.
Publicado: (2018)

Hugan Qingzhi medication ameliorates free fatty acid-induced L02 hepatocyte endoplasmic reticulum stress by regulating the activation of PKC-δ
por: Yang, Miaoting, et al.
Publicado: (2020)

Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-Based Proteomic Analysis of Hugan Qingzhi and Its Protective Properties against Free Fatty Acid-Induced L02 Hepatocyte Injury
por: Xia, Fan, et al.
Publicado: (2017)

Discovery of Quality Markers in Hugan Qingzhi Formula by Integrating a Lipid-Lowering Bioassay with UHPLC-QQQ-MS/MS
por: He, Fan, et al.
Publicado: (2020)

The Study on the Mechanism of Hugan Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin
por: Lv, Shujing, et al.
Publicado: (2021)

Lipoprotein metabolism in nonalcoholic fatty liver disease
por: Jiang, Zhenghui Gordon, et al.
Publicado: (2013)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

The role of complement in nonalcoholic fatty liver disease
por: Guo, Zhenya, et al.
Publicado: (2022)

Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota
por: Quan, Ting, et al.
Publicado: (2022)

Application of transient elastography in nonalcoholic fatty liver disease
por: Zhang, Xinrong, et al.
Publicado: (2020)

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
por: Yu, Yao, et al.
Publicado: (2018)

The implication of neutrophil extracellular traps in nonalcoholic fatty liver disease
por: Fa, Pengyan, et al.
Publicado: (2023)

Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes
por: Liu, Xiao-Lin, et al.
Publicado: (2017)

Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
por: Wai, Janae Wentong, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta‐analysis
por: Zhou, Yao‐Yao, et al.
Publicado: (2018)

Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
por: Fang, Jie, et al.
Publicado: (2022)

Comparison of hepatic gene expression profiles between three mouse models of Nonalcoholic Fatty Liver Disease
por: Xiang, Liping, et al.
Publicado: (2021)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease
por: Zhao, Li, et al.
Publicado: (2017)

Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease
por: Wang, Jin, et al.
Publicado: (2020)

Nonalcoholic fatty pancreas disease: An emerging clinical challenge
por: Zhang, Cheng-Lei, et al.
Publicado: (2021)

Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis
por: Fang, Miao, et al.
Publicado: (2020)

WGCNA-Based Identification of Hub Genes and Key Pathways Involved in Nonalcoholic Fatty Liver Disease
por: Zeng, Folai, et al.
Publicado: (2021)

Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development
por: Xu, Yan, et al.
Publicado: (2019)

Health Effects of Probiotics on Nonalcoholic Fatty Liver in the Life Cycle Based on Data Analysis
por: Wang, Jia, et al.
Publicado: (2022)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and the Kidney: A Review
por: Umbro, Ilaria, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease in obese and nonobese pediatric patients
por: Kim, Eun Jeong, et al.
Publicado: (2019)

No Evidence for a Causal Link between Serum Uric Acid and Nonalcoholic Fatty Liver Disease from the Dongfeng-Tongji Cohort Study
por: Tang, Yuhan, et al.
Publicado: (2022)

Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease
por: Zheng, Jing, et al.
Publicado: (2021)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

Protective role of arnebin-1 in rats with nonalcoholic fatty liver disease
por: Yang, Weijia, et al.
Publicado: (2019)

Emerging role of engineered exosomes in nonalcoholic fatty liver disease
por: Ding, Jian, et al.
Publicado: (2023)

Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B
por: Zhang, Siyu, et al.
Publicado: (2023)

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
por: Pei, Ke, et al.
Publicado: (2020)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k78175ik809kcbul2pu920jlh7